PB2021: QUALITY OF LIFE AND CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD): RESULTS OF A REAL-WORLD EVIDENCE STUDY. (23rd June 2022)

• Record Type: Journal Article
• Authors: Ionova, T.; Vinogradova, O.; Kochkareva, Y.; Ado, E.; Kaplanov, K.; Shirokova, M.; Shelekhova, T.; Levanov, A.; Kopylova, A.; Li, O.; Mitina, T.; Rukavitsyn, O.; Simashova, P.; Anchukova, L.; Babich, E.; Dasheeva, D.; Demchenkova, M.; Dubov, S.; Esenina, T.; Ivanova, L.; Kravchuk, T.; Rimashevskaya, E.; Saraeva, N.; Savinova, M.; Volkova, S.; Porfirieva, N.; Nikitina, T.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 1892
• Page End: 1893
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000850916.45282.84
• Languages: English
• ISSNs: 2572-9241